WO2009008461A1 - 性ホルモン感受性細胞増殖を原因とする疾患に対する医薬組成物 - Google Patents

性ホルモン感受性細胞増殖を原因とする疾患に対する医薬組成物 Download PDF

Info

Publication number
WO2009008461A1
WO2009008461A1 PCT/JP2008/062443 JP2008062443W WO2009008461A1 WO 2009008461 A1 WO2009008461 A1 WO 2009008461A1 JP 2008062443 W JP2008062443 W JP 2008062443W WO 2009008461 A1 WO2009008461 A1 WO 2009008461A1
Authority
WO
WIPO (PCT)
Prior art keywords
sex hormone
hormone sensitive
proliferation
pharmaceutical composition
hca
Prior art date
Application number
PCT/JP2008/062443
Other languages
English (en)
French (fr)
Inventor
Kazuhiro Abeyama
Yasutoshi Yamada
Shinichi Nagayama
Original Assignee
Griffin Biotech, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Griffin Biotech, Ltd. filed Critical Griffin Biotech, Ltd.
Priority to JP2009522664A priority Critical patent/JPWO2009008461A1/ja
Publication of WO2009008461A1 publication Critical patent/WO2009008461A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

　本発明の目的は、性ホルモン感受性の癌に対する抗腫瘍剤を提供することである。 　本発明により、ヒドロキシクエン酸(HCA)が、性ホルモン感受性の癌細胞の生育を抑制することが示された。HCAは、従来、急性毒性試験では、クエン酸よりも安全であることが示されており、HCAを有効成分として含有する本発明の抗腫瘍剤は、従来公知の抗腫瘍剤より副作用が小さいものと期待される。また、HCAを含む医薬組成物は、癌のみならず、性ホルモン感受性の細胞の増殖に起因するその他の疾患の治療にも役立つと考えられる。
PCT/JP2008/062443 2007-07-10 2008-07-10 性ホルモン感受性細胞増殖を原因とする疾患に対する医薬組成物 WO2009008461A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009522664A JPWO2009008461A1 (ja) 2007-07-10 2008-07-10 性ホルモン感受性細胞増殖を原因とする疾患に対する医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-180960 2007-07-10
JP2007180960 2007-07-10

Publications (1)

Publication Number Publication Date
WO2009008461A1 true WO2009008461A1 (ja) 2009-01-15

Family

ID=40228632

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/062443 WO2009008461A1 (ja) 2007-07-10 2008-07-10 性ホルモン感受性細胞増殖を原因とする疾患に対する医薬組成物

Country Status (2)

Country Link
JP (1) JPWO2009008461A1 (ja)
WO (1) WO2009008461A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011138565A1 (fr) * 2010-05-05 2011-11-10 Biorebus Association pharmaceutique contenant l'acide lipoïque, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
FR2959668A1 (fr) * 2010-05-05 2011-11-11 Biorebus Association pharmaceutique contenant l'acide lipoique, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
US20120101207A1 (en) * 2009-07-01 2012-04-26 Bridgestone Corporation Rubber-steel cord composite
US11040052B2 (en) 2013-10-03 2021-06-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BUB J.D. ET AL.: "Adiponectin as a growth inhibitor in prostate cancer cells", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 340, no. 4, 2006, pages 1158 - 1166 *
FINNEY R.E. ET AL.: "Pharmacological inhibition of phosphatidylcholine biosynthesis is associated with induction of phosphatidylinositol accumulation and cytolysis of neoplastic cell lines", CANCER RES., vol. 60, no. 18, 2000, pages 5204 - 5213 *
KIYOSE C. ET AL.: "Relationship between Garcinia cambogia-Induced Impairment of Spermatogenesis and Meiosis-Activating Sterol Production in Rat Testis", J. CLIN. BIOCHEM. NUTR., vol. 38, no. 3, 2006, pages 180 - 187 *
KRIDEL S.J. ET AL.: "Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity", CANCER RES., vol. 64, no. 6, 2004, pages 2070 - 2075 *
MAEDA O.: "Zenritsusengan ni Taisuru Naibunpitsu Ryoho", UROLOGICAL NURSING, TOKI ZOKAN, 2002, pages 92 - 106 *
SZUTOWICZ A. ET AL.: "Lipogenetic and glycolytic enzyme activities in carcinoma and nonmalignant diseases of the human breast", BR. J. CANCER, vol. 39, no. 6, 1979, pages 681 - 687 *
XU Z.X. ET AL.: "Glucocorticoid induction of fatty-acid synthase mediates the stimulatory effect of the hormone on choline-phosphate cytidyltransferase activity in fetal rat lung", BIOCHIM. BIOPHYS. ACTA, vol. 1044, no. 1, 1990, pages 70 - 76 *
YU Z. ET AL.: "Evidence that an acetate pathway for cytosolic production of acetyl CoA for lipogenesis might exist in malignant prostate cells", FASEB JOURNAL, vol. 21, no. 6, 2007, pages A1098 - A1099 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120101207A1 (en) * 2009-07-01 2012-04-26 Bridgestone Corporation Rubber-steel cord composite
WO2011138565A1 (fr) * 2010-05-05 2011-11-10 Biorebus Association pharmaceutique contenant l'acide lipoïque, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
FR2959668A1 (fr) * 2010-05-05 2011-11-11 Biorebus Association pharmaceutique contenant l'acide lipoique, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
US11040052B2 (en) 2013-10-03 2021-06-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof

Also Published As

Publication number Publication date
JPWO2009008461A1 (ja) 2010-09-09

Similar Documents

Publication Publication Date Title
TNSN07341A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
MX2011012337A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de cancer y de otras enfermedades.
MY143795A (en) Tetrahydropyridoindole derivatives
MX2011012122A (es) Derivados de tiofeno.
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
MX2010009625A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
MX341220B (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas.
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
MX2009008084A (es) Derivados de 5,6,7,8-tetrahidropteridina como inhibidores de hsp90.
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
WO2006108679A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use to combat cancer
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2012013607A (es) Polisacarido de las semillas de tamarindo para usarse en el tatamiento de enfermedades inflamatorias.
WO2009008461A1 (ja) 性ホルモン感受性細胞増殖を原因とする疾患に対する医薬組成物
WO2010075287A3 (en) Compounds and methods for the treatment of pain and other diseases
AU2005238141A8 (en) Pentenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof
WO2011058245A8 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
IL191670A0 (en) Compounds for the inhibition of apoptosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08791017

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009522664

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08791017

Country of ref document: EP

Kind code of ref document: A1